Richard Buka/X
Sep 23, 2025, 06:40
Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
Richard Buka, Chair of HaemSTAR, shared on X:
”Bit of pharma news here. CSL Behring have announced a colab with Dutch biotech, VarmX.
VarmX have been working on a very exciting molecule that is an antidote oral FXa inhibitors like rivaroxaban and apixaban.
What is this molecule? And why is it worth a potential $1.7bn?”
Stay updated with Hemostasis Today.
-
Apr 8, 2026, 07:32Giulia Simini: Acquired von Willebrand Syndrome and Coagulation Abnormalities in MPN-Associated Thrombocytosis
-
Apr 8, 2026, 07:14Julian Kyoung-Ryul Chun: Join the Discussion at EHRA 2026
-
Apr 8, 2026, 06:41Stephanie Diez de Sollano: Why Ehlers-Danlos Syndrome Deserves More Attention
-
Apr 7, 2026, 19:17Anand Padmanabhan: Persistence and Pathogenicity of Platelet Factor 4 Antibodies in VITT
-
Apr 7, 2026, 19:07Clara Meijs: Great Time Presenting Our Endometriosis Project at the AHA EPI Lifestyle Conference
-
Apr 7, 2026, 18:18Vivek Das: How Obesity, Type 2 Diabetes, and Dyslipidaemia Interact Across Multiple Cardiovascular Conditions
-
Apr 7, 2026, 17:44Augustina Isioma Ikusemoro: Quality Indicators for Red Blood Cells in Transfusion Medicine
-
Apr 7, 2026, 17:35Nikola Grubor: In Situ Pulmonary Arterial Thrombosis Mimicking CTEPH in Eisenmenger
-
Apr 7, 2026, 17:34Pooja Choradia: vWF Breakdown in Aortic Stenosis – Anaemia and Pulmonary Relevance